Key Drivers
- Liquidity cushion
- Margin compression
- Fair valuation
AIAI Summary
CLB is no longer a straightforward cyclical recovery play; the latest quarter showed how project timing and Middle East disruptions can rapidly crush margins and EBITDA, so the stock now looks like a hold only if investors believe execution normalizes soon enough to avoid a value trap.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity cushion
- •Margin compression
- •Fair valuation
CLB ended 2025 with a solid balance sheet and decent cash generation, but the latest quarter showed sharp margin compression, a small loss, and a valuation that still looks only moderately attractive.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •Oversold bounce
- •Support test
CLB has been in a steep downtrend over the last month, with lower highs/lows and a sharp 4/30 breakdown, and while RSI is deeply oversold near 20, the stock remains weak unless $13.0-$13.1 support holds.
Sharp drop from $17.29 on 2026-04-29 to $14.64 on 2026-04-30 broke support and hit momentum hard
Sentiment & News
Key News Insights:
- •Revenue pressure
- •Weak cash flow
- •Margin strain
Core Laboratories reported flat-to-lower Q1 results with weak margins, minimal free cash flow, and rising net debt as Middle East disruptions and cost pressures outweighed ongoing buybacks and dividends. ക ക
The stock may remain under pressure until regional disruptions and cost headwinds ease, despite continued shareholder returns
Similar Companies in Energy
Other companies in the same sector with AI ratings